Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology
Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement
11-Jan-2022 -
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
Mammoth Biosciences’ ...
cell therapies
CRISPR
drug development
+2